Adit Singhal

Dr. Adit Singhal


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPratik Shah
Pratik Shah
ANAnita Ng
Anita Ng
ASAndrew J Shih
Andrew J Shih
TPTony Pham
Tony Pham
JWJustin Wang
Justin Wang
DGDouglas GLADSTONE
Douglas GLADSTONE
Classic Hairy Cell Leukemia (cHCL) and related conditions are rare, indolent B-cell malignancies characterized by distinctive morphological, immunophenotypic, and molecular features. Over the past decade, major advances in understanding the pathophysiology and molecular underpinnings have reshaped diagnostic and therapeutic approaches. This review synthesizes current knowledge on the cellular origins and signaling pathways that drive cHCL and Hairy Cell Variant (HCL-v)/splenic B-cell lymphoma/leukemia (SBLPN) and other molecular aberrations in disease pathogenesis. We discuss evolving diagnostic modalities, including flow cytometry, immunohistochemistry, and next-generation sequencing, that enhance diagnostic precision and disease monitoring. Additionally, we examine established and emerging therapeutic strategies—from purine nucleoside analogs (PNA) to targeted inhibitors and immunotherapies—that have significantly improved patient outcomes while highlighting challenges such as relapse and treatment resistance. By integrating insights from molecular biology and clinical practice, this review aims to provide a comprehensive understanding of cHCL and related disorders.

6 August 2025 in Lymphatics
Verified
Journal Article
Open access
PDF file
ASAdit Singhal
Adit Singhal
DMDavid Mueller
David Mueller
BABenjamin Ascherman
Benjamin Ascherman
PSPratik Shah
Pratik Shah
WAWint Yan Aung
Wint Yan Aung
MNMaria J Nieto
Maria J Nieto
Hodgkin’s Lymphoma (HL) affects approximately 8500 individuals annually in the United States. The 5-year relative survival rate has improved to 88.5%, driven by transformative advances in immunotherapy and precision oncology. The integration of Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) has redefined treatment paradigms. The phase III SWOG S1826 trial established nivolumab plus doxorubicin, vinblastine, and dacarbazine (N + AVD) as an emerging new standard for advanced-stage HL, achieving a 2-year progression-free survival (PFS) of 92% compared to 83% for BV plus AVD (HR 0.48, 95% CI: 0.33–0.70), with superior safety, particularly in patients over 60. In relapsed/refractory HL, pembrolizumab outperforms BV, with a median PFS of 13.2 versus 8.3 months (HR 0.65, 95% CI: 0.48–0.88), as demonstrated in the KEYNOTE-204 trial. Emerging strategies, including novel ICI combinations, minimal residual disease (MRD) monitoring via circulating tumor DNA (ctDNA), and artificial intelligence (AI)-driven diagnostics, promise to further personalize therapy. This review synthesizes HL’s epidemiology, pathogenesis, diagnostic innovations, and therapeutic advances, highlighting the role of precision medicine in addressing unmet needs and disparities in HL care.

15 September 2026 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
ASAdit Singhal
Adit Singhal
SGSrinivas Govindan
Srinivas Govindan
SSSharon Santhosh
Sharon Santhosh
PSPratik Shah
Pratik Shah
CCCho Han Chiang
Cho Han Chiang
XZXin-Hua Zhu
Xin-Hua Zhu
BRAF-directed therapy achieves variable responses across solid tumors, and molecular predictors beyond mutation status remain poorly defined. We retrospectively analyzed 67 patients with BRAF-altered solid tumors across nine histologies treated with BRAF-directed therapy. VAF-defined clonality (≥5 vs <5%) and co-mutational complexity (Simple [0–1], Moderate [2–3], Complex [4+] co-altered pathways) were assessed as predictive biomarkers. Among 60 evaluable patients, ORR was 55% (95% CI: 42–67%). Patients with VAF ≥5% had significantly longer PFS than <5% (mPFS 13.2 vs 7.5 months; HR 0.36, 95% CI: 0.14–0.90; p = 0.021; clonal vs subclonal) and higher ORR (55 vs 33%). Increasing co-mutational complexity was associated with shorter PFS (HR 1.84 per tier; p = 0.009). VAF ≥5% with a simple co-mutational profile was the most favorable subgroup (ORR 70%). External validation in 17,033 BRAF-mutant samples from AACR GENIE v19.0 confirmed reproducibility of VAF distributions across institutions. We propose a hierarchical genomic framework integrating clonality and co-mutational complexity that warrants prospective validation.

25 September 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
CCCho Han Chiang
Cho Han Chiang
ASAdit Singhal
Adit Singhal
PSPratik Shah
Pratik Shah
From the 2026 National Summit on Hematologic Cancers

30 October 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
PSPratik Shah
Pratik Shah
ASAdit Singhal
Adit Singhal
FBFurkan Bahar
Furkan Bahar
TWTsu Hsien Wang
Tsu Hsien Wang
ANAnita Ng
Anita Ng
CCCho‐Han Chiang
Cho‐Han Chiang

25 March 2023
Verified
Preprint
Open access
PDF file
ASAdit Singhal
Adit Singhal
KSKelly Suchman
Kelly Suchman
ARAaron Rhee
Aaron Rhee
VAVedika Agrawal
Vedika Agrawal
JCJessica Cohen
Jessica Cohen
Splenic infarction is a rare and likely underdiagnosed complication of Epstein-Barr virus (EBV) associated infectious mononucleosis (IM). Here we describe an 18-year-old male with persistent severe left-sided abdominal pain found to be EBV positive and have a large splenic infarct, along with a transient decrease in protein C, protein S, and antithrombin III activity levels. He was treated with supportive care, and anticoagulated with heparin and apixaban. We review prior reports and perspectives on underlying pathophysiology, diagnosis, and the management of these cases which likely does not require anticoagulation although may be considered on a per case basis.